tesirine-话题@MedSci

#tesirine#

4篇内容 | 619人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1795653, encodeId=c5661e9565347, content=<a href='/topic/show?id=030a1e29024' target=_blank style='color:#2F92EE;'>#tesirine#</a>, objectTitle=全球靶向CD19 的ADC药物Loncastuximab tesirine启动关键II期研究，已完成中国临床试验首例患者给药, objectType=article, longId=217966, objectId=237d21e9664c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=237d21e9664c, replyNumber=0, likeNumber=59, createdTime=2022-07-10, rootId=0, userName=weihongyv, userId=73a3403, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=237d21e9664c, moduleTitle=全球靶向CD19 的ADC药物Loncastuximab tesirine启动关键II期研究，已完成中国临床试验首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=237d21e9664c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795652, encodeId=7b2e1e956521a, content=<a href='/topic/show?id=030a1e29024' target=_blank style='color:#2F92EE;'>#tesirine#</a>, objectTitle=Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！, objectType=article, longId=211283, objectId=6e722112837b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e722112837b, replyNumber=0, likeNumber=65, createdTime=2022-01-03, rootId=0, userName=weihongyv, userId=73a3403, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e722112837b, moduleTitle=Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e722112837b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795651, encodeId=3cf91e95651ff, content=<a href='/topic/show?id=030a1e29024' target=_blank style='color:#2F92EE;'>#tesirine#</a>, objectTitle=ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功, objectType=article, longId=186029, objectId=4575186029eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4575186029eb, replyNumber=0, likeNumber=88, createdTime=2020-03-23, rootId=0, userName=weihongyv, userId=73a3403, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4575186029eb, moduleTitle=ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4575186029eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795650, encodeId=7a4f1e9565000, content=<a href='/topic/show?id=030a1e29024' target=_blank style='color:#2F92EE;'>#tesirine#</a>, objectTitle=Lancet子刊：Rovalpituzumab tesirine作为DLL3靶向药物抗小细胞肺癌安全有效, objectType=article, longId=83756, objectId=cd1583e5618, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd1583e5618, replyNumber=0, likeNumber=72, createdTime=2016-12-20, rootId=0, userName=weihongyv, userId=73a3403, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd1583e5618, moduleTitle=Lancet子刊：Rovalpituzumab tesirine作为DLL3靶向药物抗小细胞肺癌安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd1583e5618)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

tesirine

2020-05-29

weihongyv (审核中...)

前往app查看评论内容

#tesirine#

全球靶向CD19 的ADC药物Loncastuximab tesirine启动关键II期研究，已完成中国临床试验首例患者给药

2022-07-10

weihongyv (审核中...)

前往app查看评论内容

#tesirine#

Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！

2022-01-03

weihongyv (审核中...)

前往app查看评论内容

#tesirine#

ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功

2020-03-23

weihongyv (审核中...)

前往app查看评论内容

#tesirine#

Lancet子刊：Rovalpituzumab tesirine作为DLL3靶向药物抗小细胞肺癌安全有效

2016-12-20

科室
- - 订阅+
  - 更多科室
工具
服务